| Recruiting | Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy NCT07022015 | Minia University | N/A |
| Recruiting | Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancr NCT06978322 | Minia University | — |
| Recruiting | A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenoc NCT05624918 | Ashish Manne | Phase 2 |
| Not Yet Recruiting | Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab NCT06172036 | Zhejiang University | Phase 2 |
| Recruiting | NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) NCT05529940 | Seoul National University Hospital | Phase 3 |
| Terminated | A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer NCT05546411 | Kimberly Perez, MD | Phase 2 |
| Recruiting | Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer NCT05788744 | Copenhagen University Hospital at Herlev | N/A |
| Unknown | Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic C NCT05679050 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Active Not Recruiting | Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma NCT05209074 | Case Comprehensive Cancer Center | Phase 1 |
| Terminated | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing NCT05380557 | Invitae Corporation | — |
| Withdrawn | Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer NCT03718650 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Unknown | Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemot NCT04810910 | Zhejiang Provincial People's Hospital | Phase 1 |
| Active Not Recruiting | GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarci NCT04472910 | University Health Network, Toronto | N/A |
| Active Not Recruiting | Intraoperative Radiation Therapy for Resectable Pancreatic Cancer NCT05181488 | Yona Cho | N/A |
| Unknown | Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort NCT04737551 | Shanghai Zhongshan Hospital | — |
| Recruiting | Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancrea NCT03492671 | Loma Linda University | Phase 2 |
| Withdrawn | Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients NCT03392571 | Pancreatic Cancer Research Team | Phase 2 |
| Completed | Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer NCT03435536 | University Hospital, Toulouse | N/A |
| Terminated | Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma NCT03822936 | CNAO National Center of Oncological Hadrontherapy | Phase 2 |
| Active Not Recruiting | Pre-operative Treatment for Patients With Untreated Pancreatic Cancer NCT03138720 | HonorHealth Research Institute | Phase 2 |
| Completed | Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer NCT02775695 | Medical College of Wisconsin | Phase 2 |
| Completed | A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cance NCT06363084 | Ruijin Hospital | — |
| Terminated | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study NCT02345460 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer NCT02047513 | AIO-Studien-gGmbH | Phase 2 |
| Terminated | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancre NCT02243007 | Massachusetts General Hospital | Phase 2 |
| Completed | EUS vs. MDCT in Pancreatic Malignancy NCT02115022 | Clinical Hospital Colentina | — |
| Completed | Borderline Pancreas Study: FOLFIRINOX +SBRT NCT01992705 | University of Maryland, Baltimore | EARLY_Phase 1 |
| Withdrawn | A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer NCT01694589 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Completed | Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer NCT01298011 | Pancreatic Cancer Research Team | Phase 2 |